Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease

A meta-analysis

Ruey Chen, Pi Tuan Chan, Hsin Chu, Yu Cih Lin, Pi Chen Chang, Chien Yu Chen, Kuei Ru Chou

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions. Methods: PubMed, Medline, Embase, PsycINFO, and Cochrane databases were used to search for English and non-English articles for inclusion in the meta-analysis to evaluate the effect size and incidence of adverse drug reactions of different treatments. Results: Compared with patients who received donepezil alone, those who received donepezil in combination with memantine exhibited limited improvements in cognitive functions (g = 0.378, p < .001), BPSD (g = −0.878, p < .001) and global functions (g = −0.585, p = .004). Gradual titration of memantine plus a fixed dose and gradual titration of donepezil as well as a fixed dose and gradual titration of memantine resulted in limited improvements in cognitive functions(g = 0.371, p = .005), BPSD(g = −0.913, p = .001), and global functions(g = −0.371, p = .001). Conclusion: Both in the 24th week and at the final evaluation point, the combination of donepezil and memantine led to greater improvement in cognitive functions, BPSD, and global functions than did donepezil alone in patients with moderate to severe Alzheimer Disease.

Original languageEnglish
Article numbere0183586
JournalPLoS One
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Memantine
dementia
Alzheimer disease
meta-analysis
cognition
signs and symptoms (animals and humans)
Meta-Analysis
Alzheimer Disease
titration
Behavioral Symptoms
Cognition
Dementia
Psychology
Titration
Therapeutics
dosage
incidence
drugs
donepezil
Drug-Related Side Effects and Adverse Reactions

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease : A meta-analysis. / Chen, Ruey; Chan, Pi Tuan; Chu, Hsin; Lin, Yu Cih; Chang, Pi Chen; Chen, Chien Yu; Chou, Kuei Ru.

In: PLoS One, Vol. 12, No. 8, e0183586, 01.08.2017.

Research output: Contribution to journalArticle

@article{68f57402331a44d6ab34a798b2bff368,
title = "Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis",
abstract = "Background: This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions. Methods: PubMed, Medline, Embase, PsycINFO, and Cochrane databases were used to search for English and non-English articles for inclusion in the meta-analysis to evaluate the effect size and incidence of adverse drug reactions of different treatments. Results: Compared with patients who received donepezil alone, those who received donepezil in combination with memantine exhibited limited improvements in cognitive functions (g = 0.378, p < .001), BPSD (g = −0.878, p < .001) and global functions (g = −0.585, p = .004). Gradual titration of memantine plus a fixed dose and gradual titration of donepezil as well as a fixed dose and gradual titration of memantine resulted in limited improvements in cognitive functions(g = 0.371, p = .005), BPSD(g = −0.913, p = .001), and global functions(g = −0.371, p = .001). Conclusion: Both in the 24th week and at the final evaluation point, the combination of donepezil and memantine led to greater improvement in cognitive functions, BPSD, and global functions than did donepezil alone in patients with moderate to severe Alzheimer Disease.",
author = "Ruey Chen and Chan, {Pi Tuan} and Hsin Chu and Lin, {Yu Cih} and Chang, {Pi Chen} and Chen, {Chien Yu} and Chou, {Kuei Ru}",
year = "2017",
month = "8",
day = "1",
doi = "10.1371/journal.pone.0183586",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease

T2 - A meta-analysis

AU - Chen, Ruey

AU - Chan, Pi Tuan

AU - Chu, Hsin

AU - Lin, Yu Cih

AU - Chang, Pi Chen

AU - Chen, Chien Yu

AU - Chou, Kuei Ru

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions. Methods: PubMed, Medline, Embase, PsycINFO, and Cochrane databases were used to search for English and non-English articles for inclusion in the meta-analysis to evaluate the effect size and incidence of adverse drug reactions of different treatments. Results: Compared with patients who received donepezil alone, those who received donepezil in combination with memantine exhibited limited improvements in cognitive functions (g = 0.378, p < .001), BPSD (g = −0.878, p < .001) and global functions (g = −0.585, p = .004). Gradual titration of memantine plus a fixed dose and gradual titration of donepezil as well as a fixed dose and gradual titration of memantine resulted in limited improvements in cognitive functions(g = 0.371, p = .005), BPSD(g = −0.913, p = .001), and global functions(g = −0.371, p = .001). Conclusion: Both in the 24th week and at the final evaluation point, the combination of donepezil and memantine led to greater improvement in cognitive functions, BPSD, and global functions than did donepezil alone in patients with moderate to severe Alzheimer Disease.

AB - Background: This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions. Methods: PubMed, Medline, Embase, PsycINFO, and Cochrane databases were used to search for English and non-English articles for inclusion in the meta-analysis to evaluate the effect size and incidence of adverse drug reactions of different treatments. Results: Compared with patients who received donepezil alone, those who received donepezil in combination with memantine exhibited limited improvements in cognitive functions (g = 0.378, p < .001), BPSD (g = −0.878, p < .001) and global functions (g = −0.585, p = .004). Gradual titration of memantine plus a fixed dose and gradual titration of donepezil as well as a fixed dose and gradual titration of memantine resulted in limited improvements in cognitive functions(g = 0.371, p = .005), BPSD(g = −0.913, p = .001), and global functions(g = −0.371, p = .001). Conclusion: Both in the 24th week and at the final evaluation point, the combination of donepezil and memantine led to greater improvement in cognitive functions, BPSD, and global functions than did donepezil alone in patients with moderate to severe Alzheimer Disease.

UR - http://www.scopus.com/inward/record.url?scp=85027866959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027866959&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0183586

DO - 10.1371/journal.pone.0183586

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0183586

ER -